Ephraim Mirvis

Mirvie Announces Completion of Enrollment of 10,000 Person Landmark Research Study for Pregnancy Health

Retrieved on: 
Tuesday, November 14, 2023
Science, Women, Biotechnology, Research, Health, Baby, Maternity, Consumer, Clinical Trials, Disease, Reproductive Sciences, Risk, Mortality, Pregnancy, UC San Diego Health, Ochsner Health System, Pre-eclampsia, Blood, University, RNA, Birth control, Dietary supplement, Gynaecology, Ephraim Mirvis, Obstetrics

Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.

Key Points: 
  • Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.
  • “This monumental effort represents a new chapter for pregnancy health,” said Maneesh Jain, CEO and co-founder of Mirvie.
  • “Today, we face a massive crisis in maternal health, and innovative solutions are desperately needed.
  • The audacious scale of this generalizable study – involving over 10,000 individuals – creates the largest and richest biobank of pregnancy transcriptomes ever to exist.”
    Led by internationally renowned experts in pregnancy health, the U.S.-based study seeks to understand how RNA messages found in expectant mothers’ blood can predict life-threatening pregnancy complications.

Mirvie Becomes First RNA-Based Pregnancy Health-Focused Company to Receive Clinical Laboratory Improvement Amendments (CLIA) Certification

Retrieved on: 
Tuesday, September 26, 2023
Health, Consumer, Hospitals, Health Technology, Genetics, Baby, Maternity, Biotechnology, Pregnancy, CMS, Obstetrics, Centers for Medicare & Medicaid Services, Clinical Laboratory, Bill & Melinda Gates Foundation, Parent, RNA, Certification, Medicare, CLIA, American Journal, Risk, Gynaecology, Quality control, Biology, Entrepreneurship, Research, FDA, Pregnancy Outcome Prediction study, Pharmaceutical industry, Ephraim Mirvis, Nature

Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced its South San Francisco-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.

Key Points: 
  • Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced its South San Francisco-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.
  • “We are extremely proud to have received CLIA certification, which marks a crucial milestone in our journey towards commercializing the Mirvie RNA platform,” said Maneesh Jain, Co-Founder and CEO of Mirvie.
  • “Our recent grant from the Bill and Melinda Gates Foundation, coupled with our FDA Breakthrough Device Designation last year and now CLIA certification, has given us significant momentum.
  • Mirvie predicts life-threatening complications months in advance using a patented RNA platform to reveal each pregnancy’s underlying biology.

Mirvie Receives $4.6 Million Grant to Study Objective Prediction of Preeclampsia in Sub-Saharan Africa

Retrieved on: 
Wednesday, August 2, 2023
Research, Professional Services, Philanthropy, Biometrics, Consumer, Socially Responsible Investing, Genetics, Foundation, Science, Baby, Maternity, Biotechnology, Women, Health, Pregnancy, Birmingham School of Law, University, Obstetrics, Marnix, Woman, DRS, Maternal death, Mother, LMIC, Global Health, Pre-eclampsia, Patient, Developed country, Gynaecology, Biology, Bill, Flexner Report, Entrepreneurship, Mortality, Birmingham, FDA, Bill & Melinda Gates Foundation, Alpert Medical School, Birth control, Ephraim Mirvis, Nature

Preeclampsia disproportionately impacts mothers and infants in developing countries, affecting 10 million women globally , and is a leading cause of maternal death in this population.

Key Points: 
  • Preeclampsia disproportionately impacts mothers and infants in developing countries, affecting 10 million women globally , and is a leading cause of maternal death in this population.
  • Mirvie is working to fill this need: a study published in Nature found Mirvie’s RNA platform detects 75% of those who will develop preeclampsia.
  • E Heersink School of Medicine Associate Dean for Global Health at the University of Alabama at Birmingham and co-lead researcher for the study.
  • The research funded with this grant builds upon Mirvie’s commitment to inclusive, evidence-based pregnancy health research through the Mirvie Research Collaborative.

George Rehm, JD, appointed to InkSpace Imaging Board of Directors

Retrieved on: 
Friday, April 14, 2023
UC Berkeley School of Public Health, University, Inkscape, Gender, UCB, Public health, UC, JD, Management, Ephraim Mirvis

PLEASANTON, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- InkSpace Imaging is pleased to announce the appointment of George Rehm, JD, to the company’s board of directors.

Key Points: 
  • PLEASANTON, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- InkSpace Imaging is pleased to announce the appointment of George Rehm, JD, to the company’s board of directors.
  • A trained lawyer and a founding partner of Aeris Capital, George has been engaged in healthcare investing for over 20 years.
  • "I am thrilled to have George join our Board of Directors as InkSpace Imaging transitions into its commercial stage," expressed Peter Fischer, President, and CEO of the company.
  • "George offers an abundance of valuable relationships within healthcare investment circles, as well as an impressive background in healthcare start-ups."

First Ever “Future of Pregnancy Health” Report Reveals 9 out of 10 New or Expecting Moms Want More Information About Their Individual Risk of Pregnancy Complications to Optimize Prevention

Retrieved on: 
Tuesday, November 8, 2022
Research, Medical Devices, Women, Parenting, Other Health, Biotechnology, General Health, Consumer, Health, Science, Aspirin, Liver, Parent, Ectopic pregnancy, American Heart Association, Khosla Ventures, Mortality, Population, Income, The Harris Poll, Death, Machine learning, Pre-eclampsia, Pregnancy, RNA, GV, Awareness, Placenta, NCHS, United, Entrepreneurship, Medical Affairs Bureau, Blood pressure, Education, Preterm birth, General Catalyst, Disease, Gestational diabetes, Birth certificate, Eclampsia, Marital status, Woman, Biology, Foresite Capital, CDC, Research, Seizure, Risk, Degenerative disease, Complication, White, Incidence, CEO, Birth control, Ephraim Mirvis

Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the findings of the first ever Future of Pregnancy Health Report .

Key Points: 
  • Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the findings of the first ever Future of Pregnancy Health Report .
  • The results spotlight an urgent need to identify who is most at risk of complications and tailor education and preventive care toward them.
  • The study also found new or expecting moms overwhelmingly believe knowing their risk of pregnancy complications can enable proactive, personalized and preventive pregnancy care.
  • This new approach to pregnancy health is desperately needed to chart a new course for moms in the United States.

Mirvie Expands Leadership Team with Appointment of Alison Cowan, M.D. as Head of Medical Affairs

Retrieved on: 
Tuesday, August 30, 2022
FDA, Other Health, Pharmaceutical, General Health, Women, Medical Devices, Genetics, Parenting, Children, Baby, Maternity, Family, Biotechnology, Science, Consumer, Research, Health, Machine learning, Health equity, CEO, CFRNA, RNA, Ectopic pregnancy, Research, Medical Affairs Bureau, Food and Drug Administration, Emory University, Entrepreneurship, Disease, American Journal of Obstetrics and Gynecology, Placenta, General Catalyst, Parent, Food, Northwestern University, Supplement, Infant, GV, Pre-eclampsia, Obstetrics, Multimedia, Khosla Ventures, Biology, Foresite Capital, FDA, Blue Cross Blue Shield Association, Leadership, History, Preterm birth, American Journal, Woman, Health, Pregnancy, Patient, Birth control, Medicine, Nature, Ephraim Mirvis, Gynaecology

Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the appointment of Alison Cowan, M.D., M.S.C.R.

Key Points: 
  • Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the appointment of Alison Cowan, M.D., M.S.C.R.
  • View the full release here: https://www.businesswire.com/news/home/20220830005185/en/
    As a practicing OB/GYN, Dr. Cowan brings rigorous clinical experience to our fast-growing team, said Maneesh Jain, Co-Founder and CEO of Mirvie.
  • She received her medical degree and masters in clinical research from Emory University and conducted her OB/GYN residency at Northwestern University.
  • The team at Mirvie is addressing a staggering unmet need, as 1 in 5 pregnancies are impacted by complications,[3]said Dr. Cowan.

Mirvie Raises $60 Million Funding Round to Shape the Future of Pregnancy Health

Retrieved on: 
Tuesday, May 17, 2022
Nursing, Women, Other Science, FDA, Technology, Research, Diabetes, Family, Other Health, Consumer, Parenting, Medical Devices, Baby, Maternity, Hospitals, Genetics, Clinical Trials, Other Technology, Biotechnology, Health, Science, Health, History, Disease, Doctor of Philosophy, Food, Supplement, Placenta, Patient, Biology, Woman, Parent, GV, American Journal of Obstetrics and Gynecology, Foresite Capital, General Catalyst, Research, FDA, Obstetrics, Food and Drug Administration, Awareness, BlackRock, Comerica, RNA, Pregnancy, Ectopic pregnancy, American Journal, CFRNA, Machine learning, Preterm birth, Pre-eclampsia, Khosla Ventures, Entrepreneurship, CEO, Birth control, Health insurance, Ephraim Mirvis, Nature, Gynaecology

[1],[2] Peer-reviewed, clinical evidence shows this breakthrough has the power to transform how we detect, prevent, and treat pregnancy complications.

Key Points: 
  • [1],[2] Peer-reviewed, clinical evidence shows this breakthrough has the power to transform how we detect, prevent, and treat pregnancy complications.
  • At Mirvie, we find it unacceptable that pregnancy health has not advanced meaningfully in decades, said Maneesh Jain, Co-Founder and CEO of Mirvie.
  • We believe the Mirvie RNA platform can shape a new future of predictive, preventive, and personalized pregnancy care for the well-being of millions of expecting parents and babies.
  • Mirvie is shaping the future of pregnancy health by providing women, expecting parents and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis.

Mirvie Receives FDA Breakthrough Device Designation for First Test Designed to Indicate Risk of Preeclampsia Months Before Symptoms Occur

Retrieved on: 
Tuesday, May 3, 2022
FDA, Diabetes, Other Health, General Health, Women, Medical Devices, Genetics, Parenting, Baby, Maternity, Clinical Trials, Family, Biotechnology, Science, Consumer, Research, Health, Parent, Therapy, Preterm birth, Mortality, Pregnancy, Woman, Pre-eclampsia, Mayfield (company), RNA, Khosla Ventures, Food and Drug Administration, Food, Cardiovascular disease, Placenta, American Journal, FDA, American Journal of Obstetrics and Gynecology, Diagnosis, Machine learning, CFRNA, Health, Disease, Supplement, CEO, Research, Biology, Obstetrics, Entrepreneurship, Risk, Birth control, Medical device, Vaccine, Ephraim Mirvis, Gynaecology, Nature

Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the company received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its test to indicate a womans individualized risk of developing preeclampsia before symptoms occur.

Key Points: 
  • Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the company received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its test to indicate a womans individualized risk of developing preeclampsia before symptoms occur.
  • The test is powered by the proprietary Mirvie RNA platform, which is designed to predict the risk of unexpected complications by revealing the underlying biology of each pregnancy.
  • The Mirvie Preeclampsia Test is the first test for the early identification of preeclampsia risk months before any clinical presentation of symptoms to receive FDA Breakthrough Device designation.
  • With this designation, Mirvie will continue ongoing clinical research to further validate the Mirvie Preeclampsia Test performance and improve the understanding of preeclampsia.

Study Published in The American Journal of Obstetrics and Gynecology Shows The Mirvie RNA Platform is First to Predict Preterm Birth by Revealing the Underlying Biology of Each Pregnancy

Retrieved on: 
Wednesday, April 13, 2022
Research, Women, Baby, Maternity, Genetics, Family, Biotechnology, General Health, Consumer, Health, Science, Mayfield (company), Mitchell, Pre-eclampsia, Perelman School of Medicine at the University of Pennsylvania, Woman, Preterm birth, Ectopic pregnancy, Research, Reproductive Sciences, American Journal, RNA, Khosla Ventures, Department, Machine learning, Patient, Mortality, Pregnancy, Professor, Principal, UC, University, Biology, Disease, Placenta, UC San Diego Health, American Journal of Obstetrics and Gynecology, Birth control, Vaccine, Obstetrics, Nature, Ephraim Mirvis, Gynaecology

The results demonstrate the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy.

Key Points: 
  • The results demonstrate the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy.
  • Specific RNA messages were able to predict preterm birth months before the occurrence of any symptoms.
  • This study shows the Mirvie RNA platform has the potential to transform how we detect, prevent, and treat preterm birth.
  • Early prediction of preterm birth with identification of the underlying biology creates new opportunities for pregnancy health.

Agendia Appoints Farida Peters-Abbadi as Vice President of Marketing

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Health, Clinical Trials, Other Health, Recurrence, Behavior, Â, Blueprint, Ephraim Mirvis, Growth, McGill University, Management, Research, PerkinElmer, Woman, Achievement, Binghamton University, Marie Cassidy, Quality of life, Business administration, Biology, Bachelor of Arts in Organizational Psychology, Goal, Oncology, Surgeon, Master of Business Administration, Physician, Solution, Education, Breast cancer, Patient, Prognosis, Medical imaging, Pharmaceutical industry, Marketing, MammaPrint

Farida is an exciting addition to our executive team as we focus on accelerating commercial growth and introducing new groundbreaking products and services for breast cancer patients and their physicians, said Betsy Hanna, Executive Vice President and Chief Commercial Officer at Agendia.

Key Points: 
  • Farida is an exciting addition to our executive team as we focus on accelerating commercial growth and introducing new groundbreaking products and services for breast cancer patients and their physicians, said Betsy Hanna, Executive Vice President and Chief Commercial Officer at Agendia.
  • Prior to that, she held a P&L leadership role as Vice President of Sales and Marketing at Renovia, an early-stage medical device company, where she was responsible for healthcare provider marketing, direct-to-consumer marketing, sales and customer service, partnerships, and commercial operations, ultimately delivering 80% year-over-year revenue growth.
  • My aim is to integrate my expertise as a marketing strategist into the robust efforts already underway at Agendia, said Ms. Peters-Abbadi.
  • Ms. Peters-Abbadis appointment comes as the Agendia Board and management team adds to the strong executive and operational talent in the company at all levels.